Literature DB >> 10630171

Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model.

H T Lynch1, P Watson, T G Shaw, J F Lynch, A E Harty, B A Franklin, C R Kapler, S T Tinley, B Liu, C Lerman.   

Abstract

Hereditary nonpolyposis colorectal carcinoma (HNPCC) is the most common hereditary form of colorectal carcinoma (CRC) and may account for 5-10% of the total CRC burden. The discovery of DNA mismatch repair (MMR) genes, inclusive of hMSH2, hMLH1, hPMS2, and hMSH6, has enabled the identification of who has and who does not have inordinately increased susceptibility to CRC as well as a litany of extracolonic cancers. Mutation testing has focused on hMSH2 and hMLH1, the most common mutations in HNPCC. The protocol for DNA testing and DNA-based genetic counseling is described in Part I of this study. One hundred ninety-nine bloodline relatives were tested and counseled from five hMLH1 and two hMSH2 families. Their major reason for seeking genetic counseling and DNA testing was to inform their children and other loved ones of their mutation status. Those who sought counseling overestimated their risk for inheriting the mutation and showed a high rate of interest in prophylactic surgery, and many were greatly concerned about insurance discrimination. Knowledge about HNPCC, its molecular genetic diagnosis, surveillance and management opportunities, and genetic counseling implications are still emerging, all in the face of a greater need for physician education regarding all facets of hereditary cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10630171     DOI: 10.1002/(sici)1097-0142(19991201)86:11+<2457::aid-cncr2>3.3.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Sharing genetic test results in Lynch syndrome: communication with close and distant relatives.

Authors:  Elena M Stoffel; Beth Ford; Rowena C Mercado; Darashana Punglia; Wendy Kohlmann; Peggy Conrad; Amie Blanco; Kristen M Shannon; Mark Powell; Stephen B Gruber; Jonathan Terdiman; Daniel C Chung; Sapna Syngal
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02-07       Impact factor: 11.382

2.  Features of ovarian cancer in Lynch syndrome (Review).

Authors:  Kanako Nakamura; Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Hiroyuki Nomura; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-08-20

3.  HMLH1 gene mutation in gastric cancer patients and their kindred.

Authors:  Jian-Hua Li; Xian-Zhe Shi; Shen Lü; Min Liu; Wan-Ming Cui; Li-Na Liu; Jing Jiang; Guo-Wang Xu
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

4.  Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore.

Authors:  Vivian Wei Wang; Poh Koon Koh; Wai Leng Chow; Jeremy Fung Yen Lim
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

5.  Hopefulness predicts resilience after hereditary colorectal cancer genetic testing: a prospective outcome trajectories study.

Authors:  Samuel M Y Ho; Judy W C Ho; George A Bonanno; Annie T W Chu; Emily M S Chan
Journal:  BMC Cancer       Date:  2010-06-11       Impact factor: 4.430

6.  Genetic detection of Chinese hereditary nonpolyposis colorectal cancer.

Authors:  Long Cui; Hei-Ying Jin; Hui-Yu Cheng; Yu-Di Yan; Rong-Gui Meng; De-Hong Yu
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

7.  Carrier risk status changes resulting from mutation testing in hereditary non-polyposis colorectal cancer and hereditary breast-ovarian cancer.

Authors:  P Watson; S A Narod; R Fodde; A Wagner; J F Lynch; S T Tinley; C L Snyder; S A Coronel; B Riley; Y Kinarsky; H T Lynch
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

8.  Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.

Authors:  Anja Wagner; Alicia Barrows; Juul Th Wijnen; Heleen van der Klift; Patrick F Franken; Paul Verkuijlen; Hidewaki Nakagawa; Marjan Geugien; Shantie Jaghmohan-Changur; Cor Breukel; Hanne Meijers-Heijboer; Hans Morreau; Marjo van Puijenbroek; John Burn; Stephany Coronel; Yulia Kinarski; Ross Okimoto; Patrice Watson; Jane F Lynch; Albert de la Chapelle; Henry T Lynch; Riccardo Fodde
Journal:  Am J Hum Genet       Date:  2003-03-25       Impact factor: 11.025

9.  Economic evaluation of genetic screening for Lynch syndrome in Germany.

Authors:  Franziska Severin; Björn Stollenwerk; Elke Holinski-Feder; Elisabeth Meyer; Volker Heinemann; Clemens Giessen-Jung; Wolf Rogowski
Journal:  Genet Med       Date:  2015-01-08       Impact factor: 8.822

10.  Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario.

Authors:  Yun-Hee Choi; Michelle Cotterchio; Gail McKeown-Eyssen; Monga Neerav; Bharati Bapat; Kevin Boyd; Steven Gallinger; John McLaughlin; Melyssa Aronson; Laurent Briollais
Journal:  Hered Cancer Clin Pract       Date:  2009-08-23       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.